CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

BACKGROUND: Combination treatment with chemotherapy and immune checkpoint inhibitors (ICIs) has demonstrated meaningful clinical benefit to patients. However, chemotherapy-induced damage to the immune system can potentially diminish the efficacy of chemotherapy/ICI combinations. Trilaciclib, a highl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Anne Y, Sorrentino, Jessica A, Dragnev, Konstantin H, Weiss, Jared M, Owonikoko, Taofeek K, Rytlewski, Julie A, Hood, Jill, Yang, Zhao, Malik, Rajesh K, Strum, Jay C, Roberts, Patrick J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534680/
https://www.ncbi.nlm.nih.gov/pubmed/33004541
http://dx.doi.org/10.1136/jitc-2020-000847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534680/
https://www.ncbi.nlm.nih.gov/pubmed/33004541
http://dx.doi.org/10.1136/jitc-2020-000847

Ejemplares similares